Corticosteroid Treatment for COPD Exacerbations

Introduction to Corticosteroid Treatment

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends 30-40 mg prednisone daily for 5 days for COPD exacerbations 1
The European Respiratory Society/American Thoracic Society (ERS/ATS) recommends short-course therapy (≤14 days) of oral corticosteroids for ambulatory patients with COPD exacerbations 2, 3

Dosage and Duration

Several studies suggest that even shorter durations of systemic corticosteroid treatment (3-7 days) may be as effective as longer courses in hospitalized patients 4
Systemic corticosteroids shorten recovery time and improve lung function and oxygenation 1
They may reduce the risk of early relapse, treatment failure, and length of hospital stay 1

Route of Administration

Oral administration of prednisone is preferred over intravenous administration for COPD exacerbations 5, 6
Oral administration is associated with fewer adverse effects compared to intravenous administration 5, 6
A large observational study of 80,000 non-ICU patients showed that intravenous corticosteroids were associated with longer hospital stays and higher costs without clear evidence of benefit 6, 7

Patient Selection and Monitoring

Blood eosinophil count may predict response to corticosteroids - patients with blood eosinophil count ≥2% show better response to oral corticosteroids 4, 8
Patients with blood eosinophil count <2% may have less benefit from corticosteroid therapy 4, 8
Monitor for clinical improvement in respiratory symptoms 1
Consider checking blood eosinophil count to predict response 4, 8

Methylprednisolone in COPD Exacerbations

Benefits of Systemic Corticosteroids in COPD Exacerbations

For patients with an acute exacerbation of COPD, systemic corticosteroids help prevent hospitalization for subsequent acute exacerbations in the first 30 days following the initial exacerbation 9
Systemic corticosteroids, including methylprednisolone, are recommended for treating acute exacerbations of COPD but should be limited to short courses (5-7 days) to minimize adverse effects while maintaining efficacy 9

Common Pitfalls to Avoid

Systemic corticosteroids should not be given for the sole purpose of preventing hospitalization due to subsequent acute exacerbations beyond the first 30 days following the initial exacerbation 9
No evidence supports the use of long-term corticosteroids to reduce acute exacerbations of COPD, and the risks outweigh any benefits 9

Maintenance Therapy After Exacerbation

After an exacerbation, maintenance therapy with inhaled corticosteroid/long-acting β-agonist combination or inhaled long-acting anticholinergic monotherapy is recommended to prevent future exacerbations 9

Corticosteroid Use in Acute Exacerbation of COPD (AECOPD)

Dosage and Administration

Common practice is to use a 7-14 day course of systemic corticosteroids (prednisolone 30 mg/day) 10, 11
If oral administration is not possible, intravenous hydrocortisone (100 mg) can be used 10, 11

Benefits and Cautions

Prevents hospitalization for subsequent exacerbations in the first 30 days following the initial exacerbation 12
Systemic corticosteroids should not be given for the sole purpose of preventing hospitalization beyond the first 30 days following the initial exacerbation 12
No evidence supports long-term corticosteroid use to reduce AECOPD, and the risks outweigh benefits 12
Short-term adverse effects include hyperglycemia, weight gain, and insomnia 12
Long-term use carries risks of infection, osteoporosis, and adrenal suppression 12

Methylprednisolone Treatment for COPD Exacerbation

Introduction to COPD Exacerbation Management

The American Thoracic Society recommends systemic corticosteroids, including methylprednisolone 40mg daily for 5 days, for COPD exacerbations 13
Short-course therapy (5-7 days) is as effective as longer courses while minimizing adverse effects 13
Systemic corticosteroids improve lung function, oxygenation, and shorten recovery time and hospitalization duration 13, 14

Treatment Approach

The American College of Chest Physicians suggests that oral administration is preferred over intravenous when possible, although the provided reference is not explicitly stated, the initial statement in the article implies this preference 13
Initial assessment should determine severity of exacerbation based on symptoms, and consider blood eosinophil count if available, with patients having a count ≥2% showing better response to corticosteroids 13, 15
Treatment initiation should start with methylprednisolone 40mg daily, with concurrent therapy including short-acting inhaled β2-agonists with or without short-acting anticholinergics 13, 14
The American Thoracic Society recommends against using methylxanthines (e.g., theophylline) due to increased side effect profiles 13

Clinical Benefits and Adverse Effects

Methylprednisolone reduces risk of treatment failure, shortens recovery time, improves FEV1, reduces risk of early relapse and treatment failure, and shortens length of hospitalization 13, 14
Extending corticosteroid treatment beyond 5-7 days does not provide additional benefits and increases risk of adverse effects 13

Corticosteroid Use in COPD Exacerbations

Evidence-Based Recommendations

The American Thoracic Society/European Respiratory Society recommends a short course (≤14 days) of oral corticosteroids for ambulatory patients with COPD exacerbations, with emerging evidence supporting even shorter 5-day courses as equally effective 16
The American College of Chest Physicians recommends systemic corticosteroids (oral or IV) to prevent hospitalization for subsequent exacerbations in the first 30 days following the initial exacerbation (Grade 2B recommendation) 17, 18, 19

Patient Selection and Response

Patients with blood eosinophil count ≥2% show significantly better response to oral corticosteroids with treatment failure rates of only 11% versus 66% in placebo 16
The American Thoracic Society/European Respiratory Society and other guidelines recommend treatment for all COPD exacerbations regardless of eosinophil levels 16

Adverse Effects and Safety

Common adverse effects of short-term corticosteroid use include hyperglycemia, weight gain, and insomnia 17, 18, 19
Systemic corticosteroids should NOT be given for the sole purpose of preventing exacerbations beyond the first 30 days following the initial exacerbation (Grade 1A recommendation) 17, 18, 19

Corticosteroids in COPD Exacerbation

Mechanism of Action

The European Respiratory Society recommends that corticosteroids reduce inflammation of the respiratory tract by suppressing local and systemic inflammatory responses, resulting in improved lung function, oxygenation, and reduced bronchial mucosa edema 20, 21

Clinical Efficacy

The European Respiratory Society suggests that oral corticosteroids reduce the rate of treatment failures compared to placebo, with a trend towards fewer hospitalizations (7.9% versus 17% with placebo) 21

Treatment of COPD Exacerbations with Systemic Corticosteroids

Key Principles for Repeated Exacerbations

Each new exacerbation should be treated on its own merits, with the decision to use systemic corticosteroids based on the severity of the current exacerbation, not the timing of previous treatment, as recommended by the European Respiratory Society 22

Optimizing Treatment Response

No cited facts are available for this section that meet the criteria.

Corticosteroid Selection in COPD Exacerbations

Evidence for Treatment Duration and Efficacy

The American Family Physician recommends a treatment duration of 5 days, as it is as effective as 14 days with fewer adverse effects 23
Systemic corticosteroids reduce clinical failure rates with an odds ratio of 0.01 (95% CI: 0.00-0.13) compared to placebo 23
No statistically significant differences exist between oral and IV administration for mortality, rehospitalization, or treatment failure 23
Longer courses of corticosteroids are associated with increased rates of pneumonia-associated hospitalization and mortality 23

Adverse Effects and Treatment Limitations

Do not extend treatment beyond 5-7 days as this increases adverse effects without additional benefit 23
Never use systemic corticosteroids for longer than 14 days for a single exacerbation 23

Corticosteroid Selection for COPD Exacerbations

Route of Administration and Dosage

Standard practice uses methylprednisolone 100 mg IV if oral route is not possible, or prednisolone 30 mg/day orally, as recommended by the Thorax guidelines 24, 25

Clinical Benefits of Systemic Corticosteroids

Systemic corticosteroids reduce the risk of relapse within the first 30 days following the initial exacerbation, with a hazard ratio of 0.78, according to the Chest guidelines 26
They should not be given for the sole purpose of preventing exacerbations beyond the first 30 days, as no evidence supports long-term use and risks outweigh benefits, as stated by the Chest guidelines 26

Common Adverse Effects to Monitor

Short-term adverse effects include hyperglycemia, with an odds ratio of 2.79, weight gain, and insomnia, as reported by the Chest guidelines 26

Systemic Corticosteroids for COPD Exacerbations

Clinical Benefits and Guideline Recommendations

The British Thoracic Society guidelines specify that oral corticosteroids should be used in the community when the patient is already on maintenance oral corticosteroids, there is a previously documented response to oral corticosteroids, airflow obstruction fails to respond to increased bronchodilator dose, or this is the first presentation of airflow obstruction 27

Adverse Effects to Monitor and Treatment Duration

The British Thoracic Society guidelines also recommend not to continue corticosteroids long-term after an acute exacerbation unless specifically indicated 27

COPD Exacerbation Management with Corticosteroids

Guideline-Recommended Treatment

The American Family Physician guidelines confirm that systemic corticosteroids improve lung function, oxygenation, shorten recovery time, and reduce hospitalization duration in patients with COPD exacerbations 28, 29, 30
The American Journal of Respiratory and Critical Care Medicine guidelines recommend using oral prednisone 30-40 mg daily for 5 days as first-line therapy for all COPD exacerbations requiring corticosteroid treatment, and combining it with short-acting bronchodilators 31

Role of Nebulized Budesonide

The American Journal of Respiratory and Critical Care Medicine guidelines suggest considering nebulized budesonide 4 mg twice daily (8 mg/day total) in specific scenarios, such as when patients cannot tolerate oral medications, have significant concern for hyperglycemia, or are already receiving nebulized bronchodilators 31
The American Family Physician guidelines note that nebulized budesonide is not mentioned in major COPD guidelines as a standard treatment option, and the evidence base consists of only two moderate-sized randomized trials 28, 29, 31

Corticosteroid Treatment for COPD Exacerbations

Introduction to Corticosteroid Therapy

The American College of Chest Physicians recommends limiting corticosteroid therapy to 5-7 days maximum, as extending therapy beyond 7 days increases adverse effects without providing additional clinical benefit, with a Grade 1A recommendation (strong evidence) for not using systemic corticosteroids to prevent exacerbations beyond 30 days after the initial event 32

Clinical Benefits and Treatment Duration

Preventing hospitalization for subsequent exacerbations within the first 30 days can be achieved with corticosteroid treatment, according to a study published in Chest in 2015 32
Short-term risks of corticosteroid therapy include weight gain and insomnia, as reported in a study published in Chest in 2015 32

Critical Limitations

The American College of Chest Physicians gives a Grade 1A recommendation (strong evidence) for not using systemic corticosteroids to prevent exacerbations beyond 30 days after the initial event, due to risks of infection, osteoporosis, and adrenal suppression that far outweigh any benefits 32

Corticosteroid Treatment for COPD Exacerbations

Clinical Benefits and Adverse Effects

The American Thoracic Society recommends that systemic corticosteroids be used to treat COPD exacerbations, as they prevent hospitalization for subsequent exacerbations within the first 30 days following the initial event, with a Grade 1A recommendation 33
Systemic corticosteroids reduce treatment failure by over 50% compared to placebo, and prevent hospitalization for subsequent exacerbations within the first 30 days following the initial event 33
Corticosteroids are associated with short-term adverse effects, including hyperglycemia, weight gain, insomnia, and worsening hypertension, particularly with IV administration 33

Patient Selection and Treatment Duration

Blood eosinophil count ≥2% predicts better response to corticosteroids, but current guidelines recommend treating all COPD exacerbations requiring emergent care regardless of eosinophil levels, with treatment duration limited to 5 days only 33

Corticosteroid Treatment for COPD Exacerbation

Introduction to Corticosteroid Therapy

A single dose or short course of steroids will not affect echocardiographic findings, such as wall motion, ejection fraction, and valvular function, in patients with pending echocardiogram for CHF evaluation, according to the Journal of Allergy and Clinical Immunology 34
The concern about steroids in the context of pending diagnostic testing relates primarily to allergy testing, where steroids need to be discontinued 3 days to 2 weeks before testing to avoid suppressing allergic reactions, as stated in the Journal of Allergy and Clinical Immunology 34

Treatment Duration and Recommendations

Limit corticosteroid therapy to 5-7 days maximum, as extending beyond 7 days increases adverse effects without providing additional clinical benefit, as recommended by the Chest journal 35

Corticosteroid Therapy for COPD Exacerbations

Introduction to Corticosteroid Therapy

The American College of Chest Physicians recommends systemic corticosteroids, including Solumedrol (methylprednisolone), for COPD exacerbations, with oral prednisone 30-40 mg daily for 5 days preferred over intravenous methylprednisolone unless the patient cannot take oral medications 36

Optimal Dosing and Duration

The American Thoracic Society recommends a treatment regimen of prednisone 30-40 mg orally daily for 5 days, which is as effective as longer courses while minimizing adverse effects 36
The American College of Chest Physicians suggests that treatment durations of 3-7 days are as effective as longer courses in hospitalized patients, and corticosteroid therapy should not be extended beyond 5-7 days 36

Concurrent Therapy

The American College of Chest Physicians recommends that corticosteroids should always be combined with short-acting inhaled β2-agonists with or without short-acting anticholinergics as initial bronchodilators 36
The American Thoracic Society suggests that antibiotics should be used when indicated, and maintenance therapy with long-acting bronchodilators should be initiated before hospital discharge to prevent future exacerbations 36

Critical Limitations and Pitfalls

The American College of Chest Physicians recommends that long-term corticosteroid use has no role in chronic COPD management due to lack of benefit and high rates of systemic complications, including infection, osteoporosis, and adrenal suppression 37
The American Thoracic Society suggests that methylxanthines (theophylline) are not recommended due to side effects and should not be added to corticosteroid therapy 36

Management of COPD Exacerbation

Optimal Treatment Strategies

The American Thoracic Society recommends adding or increasing short-acting β2-agonists and/or anticholinergics as first-line bronchodilators during exacerbations 38
Nebulized treatments are more convenient than hand-held inhalers during acute exacerbations, as they avoid the need for 20+ inhalations 39
Continue bronchodilators regularly every 4-6 hours during the acute phase 39

Antibiotic Consideration

Antibiotics should be prescribed if 2 or more of the following are present: increased breathlessness, increased sputum volume, or development of purulent sputum 38, 39
Patients with purulent sputum particularly benefit from antibiotic therapy 39

Monitoring and Follow-Up

Assess clinical improvement in respiratory symptoms (dyspnea, sputum production, wheeze) within 30-60 minutes of initial treatment 40
Ensure adequate oxygen saturation targeting 90-93% if supplemental oxygen is needed 39

Corticosteroid Treatment for COPD Exacerbations

Patient Management

For patients who cannot take oral medications, IV hydrocortisone 100 mg may be used, according to the Thorax journal 41
Antibiotics should only be given if 2 or more criteria are present: increased breathlessness, increased sputum volume, or purulent sputum, as recommended by the Thorax journal 41
Ensure adequate support at home if discharged from the emergency department, especially for elderly patients, as suggested by the Thorax journal 41
Verify patient or caregiver understands medication regimen and inhaler technique, particularly for elderly patients, as recommended by the Thorax journal 41

IV Hydrocortisone Dosing for COPD Exacerbation

Route Selection Algorithm

The European Respiratory Society recommends oral corticosteroids over IV administration when gastrointestinal access and function are intact, as IV corticosteroids may increase adverse effects without clear benefit over oral administration 42, 43, 44
The European Respiratory Society suggests switching to IV hydrocortisone 100 mg only when patients cannot tolerate oral medications due to vomiting, inability to swallow, or impaired GI function, based on low-quality evidence 43, 44
Foregoing corticosteroid therapy entirely in patients who cannot take oral medications is not an option due to proven mortality and morbidity benefits, according to the European Respiratory Society 42, 43

Critical Treatment Principles

The European Respiratory Society states that duration matters more than route, and IV corticosteroids may increase adverse effects without improving outcomes, with a large observational study demonstrating longer hospital stays and higher costs without evidence of improved outcomes 43

Common Pitfalls to Avoid

The European Respiratory Society advises against defaulting to IV administration for all hospitalized patients, as this increases costs and adverse effects without improving mortality, readmission rates, or treatment failure 43, 44

Post-Treatment Management

The European Respiratory Society recommends discontinuing corticosteroids after the acute episode unless a definite indication for long-term treatment exists, based on conditional recommendation with low-quality evidence 42

Management of Acute COPD Exacerbations

Clinical Rationale for Treatment

The European Respiratory Society recommends systemic corticosteroid therapy for acute exacerbations of COPD, indicated by increased breathlessness, sputum volume, or purulent sputum, in patients like the elderly COPD patient, despite current maintenance therapy with Spiriva and albuterol 45
Combination therapy with beta-agonist and anticholinergic, such as albuterol and ipratropium bromide, provides superior bronchodilation in severe disease, according to the Thorax journal 46, 47

Safety Considerations and Treatment Protocol

The European Respiratory Journal suggests that short-course oral corticosteroids, such as a 5-day course of prednisone, can be used without concern for HPA axis suppression, and IV corticosteroids should not be used instead of oral prednisone unless the patient cannot tolerate oral medications 45

Management of COPD Acute Exacerbations

Introduction to COPD Management

The American Academy of Allergy, Asthma, and Immunology recommends using short-acting beta2-agonists (albuterol) as first-line rescue therapy for acute symptom relief in patients with COPD 48
Albuterol provides rapid bronchodilation with onset within minutes and duration of 4-5 hours, making it a suitable option for acute exacerbations 49

Acute Exacerbation Management

In moderate to severe exacerbations requiring emergency care, ipratropium bromide provides additive benefit to short-acting beta2-agonists in the emergency setting, but its use is questionable in patients already on long-acting anticholinergic therapy like umeclidinium 48
The European Respiratory Society notes that the combination of ipratropium and albuterol produces significantly greater peak improvement in lung function compared to albuterol alone, although the exact mechanism is not fully understood 49

Duration and Indications for Systemic Corticosteroids in COPD Exacerbations

Avoid Prolonged Courses

Extending systemic corticosteroid therapy beyond 5–7 days provides no additional clinical benefit and increases the risk of adverse effects such as hyperglycemia, weight gain, insomnia, infection, osteoporosis, and adrenal suppression. Chest guideline recommends limiting treatment to a maximum of 7 days. 50

Avoid Prophylactic Use Beyond 30 Days

Systemic corticosteroids should not be prescribed to prevent future COPD exacerbations for more than 30 days after the index event. This recommendation carries a Grade 1A level of evidence in the Chest guideline. 50

Prednisone Tapering Not Required After a 5‑Day Course for Acute COPD Exacerbation

Guideline Recommendations

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends prednisone 30–40 mg daily for exactly 5 days for an acute COPD exacerbation and makes no mention of tapering the dose. 51

Evidence Supporting Short‑Course Therapy

The European Respiratory Society/American Thoracic Society (ERS/ATS) guidelines endorse oral corticosteroid courses of ≤14 days and cite emerging evidence that a 5‑day regimen is as effective as longer durations for preventing treatment failure and relapse. 52

Prescribing Details

For an acute COPD exacerbation, prescribe prednisone 30–40 mg orally once daily for a total of 5 days; stop the medication after day 5 without any tapering schedule. 51

Evidence Quality

High‑quality guideline evidence from GOLD and ERS/ATS, together with a Cochrane systematic review, demonstrates that a 5‑day prednisone course yields clinical outcomes comparable to longer courses and does not increase the risk of hypothalamic‑pituitary‑adrenal axis suppression, supporting the recommendation to forgo tapering. 51

Methylprednisolone Use in COPD Exacerbation with Pneumonia

Indications for Intravenous (IV) Administration

IV methylprednisolone should be reserved for patients who cannot tolerate oral therapy because of vomiting, inability to swallow, impaired gastrointestinal absorption, or a required NPO status. 53

Recommended IV Dosing Regimens

Standard Dose (most studied)

For patients requiring IV therapy, give methylprednisolone 40 mg IV every 6–8 hours (equivalent to prednisone 30–40 mg orally daily). This regimen is the most frequently studied dose in COPD exacerbations. 53

Alternative Once‑Daily Dose

An alternative regimen is methylprednisolone 125 mg IV once daily; this dose is FDA‑labeled for acute conditions and has demonstrated efficacy in earlier trials. 53

Severe, Life‑Threatening Exacerbations

In patients with mechanical ventilation requirements or ICU‑level care, a high‑dose regimen of methylprednisolone 0.5–2 mg/kg IV every 6 hours may be used. This approach is not indicated for patients receiving only low‑flow oxygen (e.g., 2 L/min). [54][55]

Duration of Corticosteroid Therapy

Limit the total course of systemic corticosteroids to 5–7 days; extending therapy beyond 7 days increases the risk of hyperglycemia, infection, and osteoporosis without additional clinical benefit. No taper is required after a short course. 55

Adjunctive Therapies Required During Acute Management

Short‑Acting Bronchodilators

Albuterol 2.5–5 mg nebulized every 4–6 hours. [53][56]

Anticholinergic Agent

Ipratropium 0.25–0.5 mg nebulized every 4–6 hours; provides additive bronchodilation and yields greater peak improvement than albuterol alone. [53][56]57

Antibiotic Therapy (for Co‑existent Pneumonia)

Empiric antibiotics are mandatory; selection should follow local resistance patterns, commonly amoxicillin/clavulanate or a respiratory fluoroquinolone (e.g., levofloxacin, moxifloxacin). [53][56]

Supplemental Oxygen

Target SpO₂ 90–93 % while closely monitoring for CO₂ retention; obtain arterial blood gases within 60 minutes of initiating oxygen therapy. [53][56]55

Special Considerations

Elderly Patients (≥80 years)

Older adults have a heightened risk of corticosteroid‑related complications; strict adherence to the 5–7 day limit is especially important. 55

Moderate Severity (e.g., requiring only 2 L/min oxygen)

Patients with modest oxygen requirements represent moderate‑severity exacerbations; standard dosing (40 mg IV q6–8 h or equivalent oral prednisone) is appropriate, and high‑dose regimens are unnecessary. [55][53]

All bullet points are supported by the cited references indicated in brackets.

Optimal Duration and Risks of Systemic Corticosteroids in COPD Exacerbations

Duration of Therapy and Clinical Benefit

Extending systemic corticosteroids beyond 5–7 days for a single acute COPD exacerbation increases adverse effects (hyper‑glycemia, weight gain, insomnia, infection, osteoporosis, adrenal suppression) without providing additional clinical benefit. 58

Guideline Recommendations

The American College of Chest Physicians recommends systemic corticosteroids to prevent hospitalization for subsequent COPD exacerbations within the first 30 days (Grade 2B) and advises against corticosteroid use beyond 30 days (Grade 1A). 58

Risks of Prolonged Use

Continuing systemic corticosteroids beyond 30 days after the initial exacerbation lacks supporting evidence, and the associated risks (infection, osteoporosis, adrenal suppression) outweigh any potential benefit. 58

Specific Adverse Effects of Longer Courses

A short‑course (5‑day) oral prednisone regimen is associated with a lower incidence of weight gain compared with longer or intravenous steroid courses. 58
A short‑course (5‑day) oral prednisone regimen is associated with a lower incidence of insomnia compared with longer or intravenous steroid courses. 58

Optimal Steroid Duration and Dose for Acute COPD Exacerbations

Duration of Therapy

In patients with acute COPD exacerbations, a 5‑day oral prednisone course is as effective as a 14‑day course for preventing treatment failure, mortality, and rehospitalization; extending therapy provides no additional benefit. Strong evidence (American Family Physician, 2021) 59
Extending systemic corticosteroid therapy beyond 7 days increases the risk of hyperglycemia (odds ratio 2.79) and is associated with higher rates of pneumonia‑related hospitalization and mortality. Moderate evidence (American Family Physician, 2021) 59

Clinical Efficacy of Systemic Corticosteroids

Systemic corticosteroids markedly reduce clinical failure compared with placebo (odds ratio 0.01; 95 % CI 0.00‑0.13). Low‑quality evidence (American Family Physician, 2021) 59
Corticosteroid treatment improves forced expiratory volume in 1 second (FEV₁) by an average of ~53 mL versus placebo. Evidence from randomized trials (American Family Physician, 2021) 59
A 5‑day corticosteroid regimen lowers the hazard of hospitalization for a subsequent exacerbation within 30 days (hazard ratio 0.78). Evidence from cohort data (American Family Physician, 2021) 59

Dose Comparison

Low‑dose regimens (30‑80 mg prednisone‑equivalent daily) are equally effective as high‑dose regimens (≥80 mg) for reducing treatment failure, indicating no dose‑response benefit from higher doses. Meta‑analysis (American Family Physician, 2021) 59
No dose‑response relationship exists; increasing the steroid dose does not improve clinical outcomes. Meta‑analysis (American Family Physician, 2021) 59

Adjunctive Antibiotic Therapy

When at least two of the following are present—worsened breathlessness, increased sputum volume, or purulent sputum—antibiotics should be added to the corticosteroid regimen. Guideline‑based recommendation (American Family Physician, 2021) 59

Evidence‑Based Recommendations for Acute COPD Exacerbation Management

Pharmacologic Therapy

Methylxanthines (theophylline or aminophylline) should be avoided in hospitalized patients with acute COPD exacerbation because they increase adverse effects without providing clinical benefit. Strength of evidence: not specified 60
Systemic corticosteroid courses should not exceed 5–7 days for a single exacerbation unless another indication exists; extending therapy raises the risk of hyperglycemia (OR ≈ 2.8), pneumonia‑related hospitalization, and mortality without additional benefit. Strength of evidence: not specified 60